Drug Product Registration in US, EUROPE, JAPAN and CANADA for New Drug and Generics

Authors

  • Thomas S. Department of Drug Regulatory Affairs, NGSM Institute of Pharmaceutical sciences, Nitte University, Mangalore, Karnataka, India
  • Dixit M. Department of Drug Regulatory Affairs, NGSM Institute of Pharmaceutical sciences, Nitte University, Mangalore, Karnataka, India
  • Charyulu R.N. Department of Drug Regulatory Affairs, NGSM Institute of Pharmaceutical sciences, Nitte University, Mangalore, Karnataka, India
  • Bengre P. Department of Drug Regulatory Affairs, NGSM Institute of Pharmaceutical sciences, Nitte University, Mangalore, Karnataka, India
  • Rao M.S. Department of Drug Regulatory Affairs, NGSM Institute of Pharmaceutical sciences, Nitte University, Mangalore, Karnataka, India
  • Shetty A Department of Drug Regulatory Affairs, NGSM Institute of Pharmaceutical sciences, Nitte University, Mangalore, Karnataka, India

DOI:

https://doi.org/10.37591/rrjodfdp.v1i3.315

Abstract

Getting a marketing approval includes various junctures such as getting drug substances from approved vendors, finished product development, clinical studies, plant inspection, dossier writing and finally submission to authorities. US, Europe, Japan and Canada are the countries which are regulated for the approval of pharmaceutical products. These countries follow the ICH guidelines for the registration of drug of drug product. But each country has different type of application for the approval of new drug and generic drug. Europe follows different kinds of procedures for the approval of drugs. There is also difference in the duration required for the approval of drug to reach the market. Even though these countries follow harmonized procedures, it is impractical to get global marketing approval at same time and launch in all the regions at one go due to different type of applications and the different procedures. This article discusses the basic requirements for a drug product to reach the market.

 

Keywords: NDA, ANDA, PMDA, TPD

Downloads

Published

2019-02-26

Issue

Vol. 1 No. 3 (2014)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.